259 related articles for article (PubMed ID: 29362132)
1. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
Pai SI; Jack Lee J; Carey TE; Westra WH; Ferrone S; Moore C; Mosunjac MB; Shin DM; Ferris RL;
Oral Oncol; 2018 Feb; 77():92-97. PubMed ID: 29362132
[TBL] [Abstract][Full Text] [Related]
2. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
[TBL] [Abstract][Full Text] [Related]
3. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.
Concha-Benavente F; Srivastava R; Ferrone S; Ferris RL
Oral Oncol; 2016 Jul; 58():52-8. PubMed ID: 27264839
[TBL] [Abstract][Full Text] [Related]
4. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
6. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.
Srivastava RM; Trivedi S; Concha-Benavente F; Hyun-Bae J; Wang L; Seethala RR; Branstetter BF; Ferrone S; Ferris RL
Cancer Immunol Res; 2015 Aug; 3(8):936-45. PubMed ID: 25972070
[TBL] [Abstract][Full Text] [Related]
7. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
10. HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status.
Cao J; Brouwer NJ; Jordanova ES; Marinkovic M; van Duinen SG; de Waard NE; Ksander BR; Mulder A; Claas FHJ; Heemskerk MHM; Jager MJ
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):1005-1015. PubMed ID: 29450544
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of PD-L1
Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
[TBL] [Abstract][Full Text] [Related]
12. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
13. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
14. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
15. The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.
Kunkle C; Rosado FG
Arch Pathol Lab Med; 2018 Jun; 142(6):719-720. PubMed ID: 29848031
[TBL] [Abstract][Full Text] [Related]
16. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.
Xu B; Jungbluth AA; Frosina D; Alzumaili B; Aleynick N; Slodkowska E; Higgins K; Ho A; Morris L; Ghossein R; Katabi N
Histopathology; 2019 Nov; 75(5):672-682. PubMed ID: 31237963
[TBL] [Abstract][Full Text] [Related]
17. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
18. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.
Raffaghello L; Nozza P; Morandi F; Camoriano M; Wang X; Garrè ML; Cama A; Basso G; Ferrone S; Gambini C; Pistoia V
Cancer Res; 2007 Jun; 67(11):5471-8. PubMed ID: 17545629
[TBL] [Abstract][Full Text] [Related]
19. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
Sabbatino F; Villani V; Yearley JH; Deshpande V; Cai L; Konstantinidis IT; Moon C; Nota S; Wang Y; Al-Sukaini A; Zhu AX; Goyal L; Ting DT; Bardeesy N; Hong TS; Fernandez-del Castillo C; Tanabe KK; Lillemoe KD; Ferrone S; Ferrone CR
Clin Cancer Res; 2016 Jan; 22(2):470-8. PubMed ID: 26373575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
